Company profile: NovAccess Global
1.1 - Company Overview
Company description
- Provider of cancer and neurological disease immunotherapies and diagnostics, combining clinical-stage asset acquisition with medical assets in the market. Through StemVax Therapeutics, develops dendritic cell-based immunotherapies for glioblastoma with TLR adjuvants, and leverages AI, bio-sensing, and blockchain-powered AI to advance diagnostics.
Products and services
- Cancer and Neurological Disease Diagnostics: NovAccess Global utilizes blockchain-enabled AI to analyze bio-sensing datasets, accelerating discovery and implementation of diagnostics for cancer and neurological diseases
- Immunotherapy Research: NovAccess Global conducts research-grade programs enhancing human immune response to cancer, focusing on novel immunotherapy approaches and accelerating assets toward market with integrated scientific and executive teams
- StemVax Therapeutics: Subsidiary develops clinical-stage, dendritic cell–based immunotherapies for brain tumor patients, specifically targeting glioblastoma and combining dendritic cell vaccination with TLR adjuvants for enhanced immune activation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NovAccess Global
Bellus Health
HQ: Canada
Website
- Description: Provider of drug development for rare diseases, starting with kidney-affecting conditions. Lead program KIACTA, a novel drug candidate, is in data review following top-line results from a Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bellus Health company profile →
Luminary Therapeutics
HQ: United States
Website
- Description: Provider of preclinical cell therapies for cancer and autoimmune diseases, including the Allogeneic Gamma 2.0+ platform for B-cell malignancies; Split Co-Stim Dual CAR targeting multiple solid tumor antigens, designed to enhance persistence and prevent T cell exhaustion; BAFF ligand-based CAR addressing BAFF, BCMA, and TACI to mitigate antigen escape; and a non-viral TcBuster transposon process for cost-efficient CAR-T manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Luminary Therapeutics company profile →
Kyverna Therapeutics
HQ: United States
Website
- Description: Provider of autologous and allogeneic anti-CD19 CAR T-cell therapies for B-cell-driven autoimmune diseases, including KYV-101 and KYV-201. Offers clinical trials in lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis, plus an expanded access program, using engineered T cells to potentially reset the immune system and achieve sustained remission.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kyverna Therapeutics company profile →
VaxGen
HQ: United States
Website
- Description: Provider of biopharmaceutical products in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VaxGen company profile →
Synaffix
HQ: The Netherlands
Website
- Description: Provider of a proprietary antibody-drug conjugate (ADC) technology platform enhancing efficacy and tolerability to treat cancer and other disorders, enabling development from any antibody. Offerings include GlycoConnect for stable ADCs, HydraSpace for improved payload performance, toxSYN linker-payloads, conversion of antibodies to bispecifics, and custom payload delivery (cytokines, TLR/STING agonists, oligonucleotides, peptides, antibiotics, cytotoxics).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synaffix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NovAccess Global
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NovAccess Global
2.2 - Growth funds investing in similar companies to NovAccess Global
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NovAccess Global
4.2 - Public trading comparable groups for NovAccess Global
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →